Effects of innate immune receptor stimulation on extracellular α-synuclein uptake and degradation by brain resident cells.


Journal

Experimental & molecular medicine
ISSN: 2092-6413
Titre abrégé: Exp Mol Med
Pays: United States
ID NLM: 9607880

Informations de publication

Date de publication:
02 2021
Historique:
received: 06 07 2020
accepted: 09 12 2020
revised: 09 12 2020
pubmed: 18 2 2021
medline: 19 2 2022
entrez: 17 2 2021
Statut: ppublish

Résumé

Synucleinopathies are age-related neurological disorders characterized by the progressive deposition of α-synuclein (α-syn) aggregates and include Parkinson's disease (PD) and dementia with Lewy bodies (DLB). Although cell-to-cell α-syn transmission is thought to play a key role in the spread of α-syn pathology, the detailed mechanism is still unknown. Neuroinflammation is another key pathological feature of synucleinopathies. Previous studies have identified several immune receptors that mediate neuroinflammation in synucleinopathies, such as Toll-like receptor 2 (TLR2). However, the species of α-syn aggregates varies from study to study, and how different α-syn aggregate species interact with innate immune receptors has yet to be addressed. Therefore, we investigated whether innate immune receptors can facilitate the uptake of different species of α-syn aggregates. Here, we examined whether stimulation of TLRs could modulate the cellular uptake and degradation of α-syn fibrils despite a lack of direct interaction. We observed that stimulation of TLR2 in vitro accelerated α-syn fibril uptake in neurons and glia while delaying the degradation of α-syn in neurons and astrocytes. Internalized α-syn was rapidly degraded in microglia regardless of whether TLR2 was stimulated. However, cellular α-syn uptake and degradation kinetics were not altered by TLR4 stimulation. In addition, upregulation of TLR2 expression in a synucleinopathy mouse model increased the density of Lewy-body-like inclusions and induced morphological changes in microglia. Together, these results suggest that cell type-specific modulation of TLR2 may be a multifaceted and promising therapeutic strategy for synucleinopathies; inhibition of neuronal and astroglial TLR2 decreases pathogenic α-syn transmission, but activation of microglial TLR2 enhances microglial extracellular α-syn clearance.

Identifiants

pubmed: 33594256
doi: 10.1038/s12276-021-00562-6
pii: 10.1038/s12276-021-00562-6
pmc: PMC8080790
doi:

Substances chimiques

Protease Inhibitors 0
Receptors, Immunologic 0
TLR2 protein, human 0
Toll-Like Receptor 2 0
alpha-Synuclein 0

Types de publication

Journal Article Research Support, N.I.H., Intramural

Langues

eng

Sous-ensembles de citation

IM

Pagination

281-290

Subventions

Organisme : BLRD VA
ID : I01 BX004312
Pays : United States
Organisme : NIA NIH HHS
ID : R01 AG018440
Pays : United States

Références

Lee, H. J., Bae, E. J. & Lee, S. J. Extracellular alpha-synuclein—a novel and crucial factor in Lewy body diseases. Nat. Rev. Neurol. 10, 92–98 (2014).
doi: 10.1038/nrneurol.2013.275
Kim, C. & Lee, S. J. Controlling the mass action of alpha-synuclein in Parkinson’s disease. J. Neurochem. 107, 303–316 (2008).
doi: 10.1111/j.1471-4159.2008.05612.x
McCann, H., Stevens, C. H., Cartwright, H. & Halliday, G. M. alpha-Synucleinopathy phenotypes. Parkinsonism Relat. Disord. 20, S62–S67 (2014).
doi: 10.1016/S1353-8020(13)70017-8
Braak, H. & Del Tredici, K. Invited Article: nervous system pathology in sporadic Parkinson disease. Neurology 70, 1916–1925 (2008).
doi: 10.1212/01.wnl.0000312279.49272.9f
Bendor, J. T., Logan, T. P. & Edwards, R. H. The function of alpha-synuclein. Neuron 79, 1044–1066 (2013).
doi: 10.1016/j.neuron.2013.09.004
Kwon, S., Iba, M., Masliah, E. & Kim, C. Targeting microglial and neuronal Toll-like receptor 2 in synucleinopathies. Exp. Neurobiol. 28, 547–553 (2019).
doi: 10.5607/en.2019.28.5.547
Guzman-Martinez, L. et al. Neuroinflammation as a common feature of neurodegenerative disorders. Front. Pharm. 10, 1008 (2019).
doi: 10.3389/fphar.2019.01008
Lim, S., Kim, H. J., Kim, D. K. & Lee, S. J. Non-cell-autonomous actions of alpha-synuclein: implications in glial synucleinopathies. Prog. Neurobiol. 169, 158–171 (2018).
doi: 10.1016/j.pneurobio.2018.06.010
Kim, C. et al. Neuron-released oligomeric alpha-synuclein is an endogenous agonist of TLR2 for paracrine activation of microglia. Nat. Commun. 4, 1562 (2013).
doi: 10.1038/ncomms2534
Kim, C. et al. LRRK2 mediates microglial neurotoxicity via NFATc2 in rodent models of synucleinopathies. Sci. Transl. Med. 12 https://doi.org/10.1126/scitranslmed.aay0399 (2020).
Campolo, M. et al. TLR4 absence reduces neuroinflammation and inflammasome activation in Parkinson’s diseases in vivo model. Brain Behav. Immun. 76, 236–247 (2019).
doi: 10.1016/j.bbi.2018.12.003
Fellner, L. et al. Toll-like receptor 4 is required for alpha-synuclein dependent activation of microglia and astroglia. Glia 61, 349–360 (2013).
doi: 10.1002/glia.22437
Shao, Q. H. et al. TLR4 deficiency has a protective effect in the MPTP/probenecid mouse model of Parkinson’s disease. Acta Pharm. Sin. 40, 1503–1512 (2019).
doi: 10.1038/s41401-019-0280-2
Stefanova, N. et al. Toll-like receptor 4 promotes alpha-synuclein clearance and survival of nigral dopaminergic neurons. Am. J. Pathol. 179, 954–963 (2011).
doi: 10.1016/j.ajpath.2011.04.013
Mao, X. et al. Pathological alpha-synuclein transmission initiated by binding lymphocyte-activation gene 3. Science 353, https://doi.org/10.1126/science.aah3374 (2016).
Ihse, E. et al. Cellular internalization of alpha-synuclein aggregates by cell surface heparan sulfate depends on aggregate conformation and cell type. Sci. Rep. 7, 9008 (2017).
doi: 10.1038/s41598-017-08720-5
Zhang, W. et al. Microglial PHOX and Mac-1 are essential to the enhanced dopaminergic neurodegeneration elicited by A30P and A53T mutant alpha-synuclein. Glia 55, 1178–1188 (2007).
doi: 10.1002/glia.20532
Surguchev, A. A., Emamzadeh, F. N. & Surguchov, A. Cell responses to extracellular alpha-synuclein. Molecules 24, https://doi.org/10.3390/molecules24020305 (2019).
Kim, C. et al. beta1-integrin-dependent migration of microglia in response to neuron-released alpha-synuclein. Exp. Mol. Med. 46, e91 (2014).
doi: 10.1038/emm.2014.6
Fields, J., Cisneros, I. E., Borgmann, K. & Ghorpade, A. Extracellular regulated kinase 1/2 signaling is a critical regulator of interleukin-1beta-mediated astrocyte tissue inhibitor of metalloproteinase-1 expression. PLoS ONE 8, e56891 (2013).
doi: 10.1371/journal.pone.0056891
Kim, C. et al. Antagonizing neuronal Toll-like receptor 2 prevents synucleinopathy by activating autophagy. Cell Rep. 13, 771–782 (2015).
doi: 10.1016/j.celrep.2015.09.044
Lee, H. J., Khoshaghideh, F., Patel, S. & Lee, S. J. Clearance of alpha-synuclein oligomeric intermediates via the lysosomal degradation pathway. J. Neurosci. 24, 1888–1896 (2004).
doi: 10.1523/JNEUROSCI.3809-03.2004
Kim, C. et al. Exposure to bacterial endotoxin generates a distinct strain of alpha-synuclein fibril. Sci. Rep. 6, 30891 (2016).
doi: 10.1038/srep30891
Masliah, E. et al. Dopaminergic loss and inclusion body formation in alpha-synuclein mice: implications for neurodegenerative disorders. Science 287, 1265–1269 (2000).
doi: 10.1126/science.287.5456.1265
Spencer, B. et al. ESCRT-mediated uptake and degradation of brain-targeted alpha-synuclein single chain antibody attenuates neuronal degeneration in vivo. Mol. Ther. 22, 1753–1767 (2014).
doi: 10.1038/mt.2014.129
Kim, C. et al. Hypoestoxide reduces neuroinflammation and alpha-synuclein accumulation in a mouse model of Parkinson’s disease. J. Neuroinflamm. 12, 236 (2015).
doi: 10.1186/s12974-015-0455-9
Lee, H. J., Suk, J. E., Bae, E. J. & Lee, S. J. Clearance and deposition of extracellular alpha-synuclein aggregates in microglia. Biochem. Biophys. Res. Commun. 372, 423–428 (2008).
doi: 10.1016/j.bbrc.2008.05.045
Kim, C. et al. Immunotherapy targeting Toll-like receptor 2 alleviates neurodegeneration in models of synucleinopathy by modulating alpha-synuclein transmission and neuroinflammation. Mol. Neurodegener. 13, 43 (2018).
doi: 10.1186/s13024-018-0276-2
Dzamko, N. et al. Toll-like receptor 2 is increased in neurons in Parkinson’s disease brain and may contribute to alpha-synuclein pathology. Acta Neuropathol. 133, 303–319 (2017).
doi: 10.1007/s00401-016-1648-8
La Vitola, P. et al. Alpha-synuclein oligomers impair memory through glial cell activation and via Toll-like receptor 2. Brain Behav. Immun. 69, 591–602 (2018).
doi: 10.1016/j.bbi.2018.02.012
Lashuel, H. A., Overk, C. R., Oueslati, A. & Masliah, E. The many faces of alpha-synuclein: from structure and toxicity to therapeutic target. Nat. Rev. Neurosci. 14, 38–48 (2013).
doi: 10.1038/nrn3406
Desplats, P. et al. Inclusion formation and neuronal cell death through neuron-to-neuron transmission of alpha-synuclein. Proc. Natl Acad. Sci. USA 106, 13010–13015 (2009).
doi: 10.1073/pnas.0903691106
Danzer, K. M. et al. Exosomal cell-to-cell transmission of alpha synuclein oligomers. Mol. Neurodegener. 7, 42 (2012).
doi: 10.1186/1750-1326-7-42
Hansen, C. et al. alpha-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells. J. Clin. Investig. 121, 715–725 (2011).
doi: 10.1172/JCI43366
Kakuda, K. et al. Ultrasonication-based rapid amplification of alpha-synuclein aggregates in cerebrospinal fluid. Sci. Rep. 9, 6001 (2019).
doi: 10.1038/s41598-019-42399-0
Manne, S. et al. Ultrasensitive detection of aggregated alpha-synuclein in glial cells, human cerebrospinal fluid, and brain tissue using the RT-QuIC assay: new high-throughput neuroimmune biomarker assay for Parkinsonian disorders. J. Neuroimmune Pharm. 14, 423–435 (2019).
doi: 10.1007/s11481-019-09835-4
Guerrero-Ferreira, R. et al. Cryo-EM structure of alpha-synuclein fibrils. Elife 7, https://doi.org/10.7554/eLife.36402 (2018).
Guerrero-Ferreira, R., Kovacik, L., Ni, D. & Stahlberg, H. New insights on the structure of alpha-synuclein fibrils using cryo-electron microscopy. Curr. Opin. Neurobiol. 61, 89–95 (2020).
doi: 10.1016/j.conb.2020.01.014
Van der Perren, A. et al. The structural differences between patient-derived alpha-synuclein strains dictate characteristics of Parkinson’s disease, multiple system atrophy and dementia with Lewy bodies. Acta Neuropathol. 139, 977–1000 (2020).
doi: 10.1007/s00401-020-02157-3

Auteurs

Changyoun Kim (C)

Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. changyoun.kim@nih.gov.

Somin Kwon (S)

Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA.

Michiyo Iba (M)

Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA.

Brian Spencer (B)

Department of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.

Edward Rockenstein (E)

Department of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.

Michael Mante (M)

Department of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.

Anthony Adame (A)

Department of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.

Soo Jean Shin (SJ)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.

Jerel A Fields (JA)

Department of Psychiatry, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.

Robert A Rissman (RA)

Department of Neurosciences, School of Medicine, University of California, La Jolla, San Diego, CA, 92093, USA.

Seung-Jae Lee (SJ)

Department of Biomedical Sciences, Neuroscience Research Institute, and Department of Medicine, Seoul National University College of Medicine, Seoul, 03080, Korea.

Eliezer Masliah (E)

Molecular Neuropathology Section, Laboratory of Neurogenetics, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. eliezer.masliah@nih.gov.
Division of Neuroscience, National Institute on Aging, National Institutes of Health, Bethesda, MD, 20892, USA. eliezer.masliah@nih.gov.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH